Experimentally, navitoclax kills cells within a BAX/BAK-dependent method and results in regression of lymphoid tumors in xenograft products. The mix of navitoclax and irradiation exhibited a powerful synergy whatever the p53 mutation standing. (a) The most synergistic location scores for the navitoclax–irradiation mix across thirteen HNSCC mobile traces. (b) A https://julianp887cny0.wikibriefing.com/user